[{"id":"5ac6cf9e-efcf-436f-8803-ff8e9e904ab6","acronym":"RPT835GC1B","url":"https://clinicaltrials.gov/study/NCT04071184","created_at":"2021-01-18T19:55:52.106Z","updated_at":"2024-07-02T16:36:55.182Z","phase":"Phase 1b","brief_title":"Study of Alofanib in Patients With Metastatic Gastric Cancer","source_id_and_acronym":"NCT04071184 - RPT835GC1B","lead_sponsor":"Russian Pharmaceutical Technologies","biomarkers":" FGFR2 • FRS2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression","tags":["FGFR2 • FRS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alofanib (RPT835)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 05/26/2019","start_date":" 05/26/2019","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-09-26"}]